Cover Image
Market Research Report

Biosimilars Market Access in Psoriatic Arthritis

Published by Datamonitor Healthcare Product code 498963
Published Content info 24 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimilars Market Access in Psoriatic Arthritis
Published: March 23, 2017 Content info: 24 Pages
Description

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.

Table of Contents
Product Code: DMKC0170781

TABLE OF CONTENTS

EXECUTIVE SUMMARY

US

  • Inflectra carries biosimilar labeling designation, but is not interchangeable
  • Physicians hesitant to use biosimilars, but understand that payers may hold sway
  • Bibliography

FIVE MAJOR EU MARKETS

  • Insights and strategic recommendations
  • Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
  • Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
  • Payers use biosimilars to pressure originators on pricing
  • Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Biosimilars will be used as price benchmarks for pipeline agents
  • Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
  • Bibliography

METHODOLOGY

  • Primary research

LIST OF TABLES

  • Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Back to Top